Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.

Ulrike LeiterCarmen LoquaiLydia ReinhardtDavid Rafei-ShamsabadiRalf GutzmerKatharina KaehlerLucie HeinzerlingJessica C HasselValerie GlutschJudith SirokayNora SchlechtAlbert RübbenThilo GambichlerKerstin SchattonClaudia PfoehlerCindy FranklinPatrick TerheydenSebastian HaferkampPeter MohrLena BischofElisabeth LivingstoneLisa ZimmerMichael WeichenthalDirk SchadendorfAndreas MeiwesUlrike KeimClaus GarbeJürgen Christian Becker Selma Ugurel

Published in: Journal for immunotherapy of cancer (2021)

ICI therapy showed efficacy in advanced patients with skin cancer with a concomitant hematological malignancy. Compared with patients without hematological malignancy, the observed ICI therapy outcome was impaired in cSCC, but not in MM or MCC patients.

Keyphrases

skin cancer
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
stem cells
patient reported outcomes
mesenchymal stem cells
cell therapy